Aardvark Therapeutics

AARDPhase 3

Aardvark Therapeutics is pioneering a novel approach to metabolic health by targeting the neurological distinction between hunger and appetite. The company's lead program, ARD-101, is advancing through clinical development with a focus on hyperphagia in Prader-Willi Syndrome and potential expansion into general obesity. With a strengthened board featuring industry veterans from Merck and Akamara, Aardvark is positioning itself to become a leader in hunger-focused therapeutics for both rare and common metabolic conditions.

Market Cap

$88.6M

Focus

Small Molecules

AARD · Stock Price

USD 4.0710.24 (-71.56%)

Historical price data

AI Company Overview

Technology Platform

Oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) in the gut to trigger local release of satiety hormones and activate gut-brain signals that suppress hunger, with primarily localized digestive tract action.

Pipeline Snapshot

6 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Placebo + ARD-101	Hyperphagia	Phase 3
ARD-101	Hyperphagia	Phase 3
ARD-101	Prader-Willi Syndrome	Phase 2
Low Dose ARD-501 + High Dose ARD-501 + Placebo	Autism Spectrum Disorder	Phase 2
ARD-101	Bariatric Surgery	Phase 2

Opportunities

Aardvark has significant growth opportunities in both the orphan drug market for Prader-Willi Syndrome and the massive global obesity market.

Success in rare disease could provide accelerated regulatory pathways and proof-of-concept for expansion into broader metabolic indications, while the novel gut-localized mechanism may enable combination therapies with existing treatments.

Risk Factors

Key risks include clinical trial failures typical of drug development, intense competition in the obesity therapeutic space from well-funded pharmaceutical companies, challenges in securing adequate financing for late-stage trials, and the unproven nature of targeting gut bitter taste receptors for systemic metabolic effects.

Competitive Landscape

Aardvark faces competition from established players like Novo Nordisk and Eli Lilly in obesity, and from Soleno Therapeutics and Ferring in Prader-Willi Syndrome. Its differentiation lies in the novel gut-localized mechanism targeting bitter taste receptors rather than incretin pathways, potentially offering improved safety and tolerability profiles compared to systemic therapies.